Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
2010 2
2012 3
2013 1
2017 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
AIDA STEMI: no benefit for intracoronary abciximab.
Bertrand OF, Jolly S. Bertrand OF, et al. Lancet. 2012 Mar 10;379(9819):875-877. doi: 10.1016/S0140-6736(12)60079-8. Epub 2012 Feb 21. Lancet. 2012. PMID: 22357108 No abstract available.
[Bioresorbable coronary scaffolds: follow-up].
Elias J, Piek JJ. Elias J, et al. Ned Tijdschr Geneeskd. 2017;161:D2107. Ned Tijdschr Geneeskd. 2017. PMID: 29241467 Dutch.
Despite earlier acceptable short-term results, the recently published AIDA study found that the most-used resorbable scaffold (Absorb) presents an almost threefold increased risk of stent thrombosis than the metal XIENCE stent, short-term as well as long-term. ...With new …
Despite earlier acceptable short-term results, the recently published AIDA study found that the most-used resorbable scaffold (Absorb …
Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.
Kubica J, Koziński M, Navarese EP, Tantry US, Grześk G, Fabiszak T, Kubica A, Świątkiewicz I, Bliden KP, Gurbel PA. Kubica J, et al. Cardiol J. 2012;19(3):230-42. doi: 10.5603/cj.2012.0044. Cardiol J. 2012. PMID: 22641541 Free article. Review.
RESULTS: IC abciximab did not provide any benefits in terms of all-cause mortality as compared with IV abciximab (odds ratio [OR] 0.67; 95% confidence interval [CI] 0.34-1.34). However, this neutral effect was driven by the AIDA STEMI trial. The IC route was associated wit …
RESULTS: IC abciximab did not provide any benefits in terms of all-cause mortality as compared with IV abciximab (odds ratio [OR] 0.67; 95% …
The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy.
Tijssen RYG, Kerkmeijer LSM, Takahashi K, Kogame N, Katagiri Y, Kraak RP, Chichareon P, Modolo R, Asano T, Nassif M, Kalkman DN, Sotomi Y, Collet C, Hofma SH, van der Schaaf RJ, Arkenbout EK, Weevers APJD, Piek JJ, Tijssen JGP, Henriques JP, de Winter RJ, Onuma Y, Serruys PW, Wykrzykowska JJ. Tijssen RYG, et al. Int J Cardiovasc Imaging. 2020 Apr;36(4):565-575. doi: 10.1007/s10554-019-01756-w. Epub 2020 Jan 2. Int J Cardiovasc Imaging. 2020. PMID: 31898006 Clinical Trial.
It has been hypothesized that dedicated optimized Absorb BVS implantation techniques might mitigate the risk of adverse events such as target vessel failure and device thrombosis. In this explorative AIDA trial QCA substudy, we sought to investigate the influence of implan …
It has been hypothesized that dedicated optimized Absorb BVS implantation techniques might mitigate the risk of adverse events such as targe …
Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.
Eitel I, Wöhrle J, Suenkel H, Meissner J, Kerber S, Lauer B, Pauschinger M, Birkemeyer R, Axthelm C, Zimmermann R, Neuhaus P, Brosteanu O, de Waha S, Desch S, Gutberlet M, Schuler G, Thiele H. Eitel I, et al. J Am Coll Cardiol. 2013 Apr 2;61(13):1447-54. doi: 10.1016/j.jacc.2013.01.048. Epub 2013 Feb 27. J Am Coll Cardiol. 2013. PMID: 23466078 Free article. Clinical Trial.
BACKGROUND: The AIDA STEMI trial randomized 2,065 patients to intracoronary or intravenous abciximab and found similar rates of major adverse cardiac events at 90 days with significantly less congestive heart failure in the intracoronary abciximab group. CMR can directly v …
BACKGROUND: The AIDA STEMI trial randomized 2,065 patients to intracoronary or intravenous abciximab and found similar rates of major …
Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial.
Thiele H, Wöhrle J, Neuhaus P, Brosteanu O, Sick P, Prondzinsky R, Birkemeyer R, Wiemer M, Kerber S, Schuehlen H, Kleinertz K, Axthelm C, Zimmermann R, Rittger H, Braun-Dullaeus RC, Lauer B, Burckhardt W, Ferrari M, Bergmann MW, Hambrecht R, Schuler G; Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) Investigators. Thiele H, et al. Am Heart J. 2010 Apr;159(4):547-54. doi: 10.1016/j.ahj.2009.12.038. Am Heart J. 2010. PMID: 20362711 Clinical Trial.
STUDY DESIGN: The Abciximab Intracoronary versus intravenously Drug Application in STEMI (AIDA STEMI) study is a 1,912-patient, prospective, multicenter, randomized, open-label, controlled trial. ...Patients will be randomized in a 1:1 fashion to 1 of the 2 treatments. The …
STUDY DESIGN: The Abciximab Intracoronary versus intravenously Drug Application in STEMI (AIDA STEMI) study is a 1,912-patient, prosp …
A prospective multicenter registry of 0.010-inch guidewire and compatible system for chronic total occlusion: the PIKACHU registry.
Matsukage T, Masutani M, Yoshimachi F, Takahashi A, Katsuki T, Saito S, Terai H, Katahira Y, Uehara Y, Tohara S, Ohba Y, Shinohara S, Asano H, Matsumura T, Hata T, Ikari Y; PIKACHU Registry Investigators. Matsukage T, et al. Catheter Cardiovasc Interv. 2010 Jun 1;75(7):1006-12. doi: 10.1002/ccd.22434. Catheter Cardiovasc Interv. 2010. PMID: 20517961
OBJECTIVES: The aim of this study was to evaluate the safety and effectiveness of a 0.010-inch guidewire and a balloon catheter for treatment of chronic total occlusion (CTO). BACKGROUND: Pathological studies have shown that 60-70% of CTO lesions have microchannels of size …
OBJECTIVES: The aim of this study was to evaluate the safety and effectiveness of a 0.010-inch guidewire and a balloon catheter for t …
Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.
Thiele H, Wöhrle J, Hambrecht R, Rittger H, Birkemeyer R, Lauer B, Neuhaus P, Brosteanu O, Sick P, Wiemer M, Kerber S, Kleinertz K, Eitel I, Desch S, Schuler G. Thiele H, et al. Lancet. 2012 Mar 10;379(9819):923-931. doi: 10.1016/S0140-6736(11)61872-2. Epub 2012 Feb 21. Lancet. 2012. PMID: 22357109 Clinical Trial.
BACKGROUND: Intracoronary administration of an abciximab bolus during a primary percutaneous coronary intervention results in a high local drug concentration, improved perfusion, and reduction of infarct size compared with intravenous bolus application. ...INTERPRETATION: …
BACKGROUND: Intracoronary administration of an abciximab bolus during a primary percutaneous coronary intervention results in a high …
[Early and late results of CABG and PTCA].
Simizu T, Sakamoto S, Aida H, Nakajima M, Takekoshi Y, Matsui S. Simizu T, et al. Rinsho Kyobu Geka. 1987;7(1):27-33. Rinsho Kyobu Geka. 1987. PMID: 9301753 Japanese. No abstract available.